Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Dec 9, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K filing on 12/9/24 - check the press release for deets.
AI Summary
Innate Pharma SA filed a Form 6-K on December 9, 2024, reporting a press release dated the same day. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release.
Why It Matters
This filing indicates Innate Pharma is providing an update to the market, likely containing important news for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily announces the release of a press release, without disclosing new material financial or operational information within the filing itself.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- December 9, 2024 (date) — Filing and Press Release Date
- 001-39084 (other) — SEC File Number
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release issued by Innate Pharma SA on December 9, 2024.
What is the filing date of this report?
The filing date of this report is December 9, 2024.
What is the SEC file number for Innate Pharma SA?
The SEC file number for Innate Pharma SA is 001-39084.
Does Innate Pharma SA file annual reports under Form 20-F or 40-F?
Innate Pharma SA files annual reports under Form 20-F, as indicated by the checkmark in the filing.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated December 9, 2024, is included with this 6-K filing.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-12-09 06:04:54
Filing Documents
- a6k-iphx241209.htm (6-K) — 8KB
- exhibit991-241209.htm (EX-99.1) — 30KB
- 0001598599-24-000098.txt ( ) — 40KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date December 9, 2024 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chairman of the Executive Board and Chief Executive officer